Indaptus Therapeutics is a clinical biotechnology company developing a patented, systemically-administered anti-cancer and anti-viral immunotherapy. The company's technology utilizes single strains of attenuated, non-pathogenic, Gram-negative bacteria designed to activate innate and adaptive immune cells. Its lead clinical candidate, Decoy20, is an intravenous immunotherapy intended for the treatment of advanced solid tumors. The company initiated a Phase 1 clinical trial for Decoy20 in 2023 and subsequently evaluated a combination study with BeOne’s anti-PD-1 antibody, Tislelizumab, though enrollment in this study has been discontinued. Indaptus has no current plans to initiate new clinical trials and is evaluating strategic options for a post-investment transaction, including potential acquisitions or investments in target companies.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage indaptusrx.com
Sector Healthcare IR page indaptusrx.com/investors
Tags
immunotherapy, oncology, anti-viral, solid tumors, clinical-stage, bacterial immunotherapy, innate immunity, adaptive immunity, checkpoint therapy combination, Decoy20, Tislelizumab
Press page —

Metrics

Valuation  
Market cap $ 306.457M
Market cap (USD) $ 306.457M
P/E —
PEG —
P/BV 29.66
P/S —
P/OCF -22.59
P/FCF -20.67
Dividend yield —
Turnover / mcap —
Returns  
ROE -587.6%
ROI -661.5%
ROIC -472.0%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 71
Quality score -88.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 9.31M 7.339M 14.924M 28.064M 40.577M 1.778M
Net profit -20.849M -15.022M -15.423M -14.323M -7.711M -3.584M
Free cash flow -14.823M -12.323M -13.405M -13.078M -11.294M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 2.91 0.84 1.76 1.45 5.7 —
Price performance 12m 2.46 -0.52 0.21 -0.75 — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) 934,000 169,327 80,494 175,053 84,164 —
Cash and deposits (USD) 14.7M 39.1M 9.63M 13.4M 5.79M 8.51M
Right-of-use assets (USD) 817,000 169,088 79,294 173,206 82,175 —
Cash flow detail
Operating cash flow (USD) -3.32M -11.3M -13.1M -13.4M -12.3M -14.8M
Purchases of property, plant and equipment (USD) — -3,854 — — — —
Change in payables (cash effect) (USD) 113,900 -4.24M -1.15M -680,520 — —
Income taxes paid (cash effect) (USD) -800 -800 -2,400 -1,600 -1,600 —
Share-based compensation (USD) 139,960 1.51M 2.96M 2.97M 2.31M 1.36M
Free cash flow (OCF - PPE - intangibles) (USD) — -11.3M — — — —
Income detail
Research and development expense (USD) 2.66M 2.52M 6.32M 7.62M 7.25M 9.34M
↳ 5y CAGR +28.6%
Total comprehensive income (USD) — -7.71M -14.2M -15.5M -15M —
Comprehensive income to owners (USD) — -7.71M -14.2M -15.5M -15M —
Reported Mar 21, 2022 Mar 17, 2023 Mar 17, 2023 Mar 13, 2024 Mar 13, 2025 Mar 17, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

NEW YORK (November 13, 2026) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today announced financial results for the third quarter and nine months ended September 30, 2026, and provided a corporate update.

Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board, commented, “Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company’s strategic focus into promising areas of medical innovation. We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.

“We are particularly excited about the opportunity to explore the potential of an innovative neurotechnology- and neural-network-based device for certain sleep-related conditions.

Indaptus Therapeutics, Inc. — Other Events Bull 0 Bear 6 Financing

On October 16, 2026, the Company completed the Private Placement, having received the full purchase price from each of the Purchasers in accordance with the terms of the Purchase Agreement, as amended. In connection with the closing of the Private Placement, the Company will issue an aggregate of 20,338,974 Shares to the Purchasers.

As previously disclosed in the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. (the “Company”) with the Securities and Exchange Commission on September 9, 2026 (the “Prior Form 8-K”), on September 8, 2026, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with the purchasers party thereto (collectively, the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, in a private placement, shares of the Company’s common stock, par value $0.01 per share, for aggregate gross proceeds of approximately $24.0 million, before deducting offering expenses.

Pursuant to the Purchase Agreement, the closing of the transactions contemplated thereby was required to occur no later than September 29, 2026 (the “Outside Date”).

On September 29, 2026, the Company and the Purchasers entered into notices and consents (the “Notices and Consents”) pursuant to which, among other things, the Outside Date applicable to each Purchaser was extended from September 29, 2026 to October 16, 2026 (the “Extended Outside Date”).

Prompts

Indaptus Therapeutics, Inc. (ticker INDP), listed in United States.

Company History

Date Change Detail
Aug 5, 2021 Renamed INTEC PARENT INC. → INDAPTUS THERAPEUTICS, INC.

ETFs Holding Indaptus Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
MSSM 0.00% 11,002 $ 12.597K Aug 31, 2026